PT-141
Also known as
PT-141 is catalogued in the Peptides Pub research index, with coverage focused on Cognition & mood.
Evidence
Strong human RCT or meta-analysis
Risk band
Known AEs, monitoring advised
Research goals
Summary
PT-141 (bremelanotide) is a synthetic cyclic peptide analogue of alpha-melanocyte-stimulating hormone that acts as a melanocortin receptor agonist with high affinity for the melanocortin type 4 receptor, which is thought to be important for sexual function [2,4]. It is FDA-approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women and is a self-administered, on-demand subcutaneous therapy supported by Phase 3 clinical trials [2]. Studies showed improvements in desire, arousal, and orgasm scores at the recommended 1.75 mg subcutaneous dose given before sexual activity [4]. Safety signals include mild serum enzyme elevations during therapy and rare instances of clinically apparent acute liver injury [1]. Its cyclic peptide structure and low molecular weight make clinically important transfer into breastmilk unlikely, though data during breastfeeding are lacking and caution is advised [3].
Sources
- 1. Bremelanotide LiverTox, 2012.
- 2. Bremelanotide: First Approval Drugs, 2019.
- 3. Bremelanotide Drugs and Lactation Database (LactMed), 2006.
- 4. Bremelanotide for Treatment of Female Hypoactive Sexual Desire Neurology international, 2022.
For educational purposes only.